Sienna Biopharmaceuticals, Inc.
Sienna Biopharmaceuticals, Inc.
Your view on SNNAQ
Overview
What the company does, where it operates, and who runs it.
About Sienna Biopharmaceuticals, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David E. I. Pyott
- Headquarters
- 30699 Russell Ranch Road, Westlake Village, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David E. I. Pyott
- Headquarters
- 30699 Russell Ranch Road, Westlake Village, CA, US
Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin.
The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair.
The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California.
On December 18, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 16, 2019.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Sienna Biopharmaceuticals, Inc., and the rating behind it. SNNAQ last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Sienna Biopharmaceuticals, Inc.. Starting points for Sienna Biopharmaceuticals, Inc.: EPS -$3.59, beta -2.61 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Sienna Biopharmaceuticals, Inc.. Sienna Biopharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Sienna Biopharmaceuticals, Inc.. Trailing twelve-month EPS for Sienna Biopharmaceuticals, Inc. stands at -$3.59. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Sienna Biopharmaceuticals, Inc.. Sienna Biopharmaceuticals, Inc. has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Sienna Biopharmaceuticals, Inc. valued side by side against its closest peers. Sienna Biopharmaceuticals, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Sienna Biopharmaceuticals, Inc., and how their positions are changing. At a $3,091 market value, institutional positions materially move Sienna Biopharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Sienna Biopharmaceuticals, Inc. executives and directors. Shares of Sienna Biopharmaceuticals, Inc. have traded between $0.0001 and $0.0001 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Sienna Biopharmaceuticals, Inc.. Sienna Biopharmaceuticals, Inc. is a $3,091 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Sienna Biopharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Sienna Biopharmaceuticals, Inc.. Coverage tracks Sienna Biopharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.